{"protocolSection":{"identificationModule":{"nctId":"NCT01464307","orgStudyIdInfo":{"id":"MRZ 60201/SP/3002"},"secondaryIdInfos":[{"id":"2010-024579-23","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Merz Pharmaceuticals GmbH","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke","officialTitle":"Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Post-stroke Spasticity of the Lower Limb","acronym":"PLUS"},"statusModule":{"statusVerifiedDate":"2016-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-12"},"primaryCompletionDateStruct":{"date":"2014-08","type":"ACTUAL"},"completionDateStruct":{"date":"2015-05","type":"ACTUAL"},"studyFirstSubmitDate":"2011-11-01","studyFirstSubmitQcDate":"2011-11-01","studyFirstPostDateStruct":{"date":"2011-11-03","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-07-26","resultsFirstSubmitQcDate":"2016-11-04","resultsFirstPostDateStruct":{"date":"2016-11-06","type":"ESTIMATED"},"dispFirstSubmitDate":"2015-07-31","dispFirstSubmitQcDate":"2015-07-31","dispFirstPostDateStruct":{"date":"2015-08-21","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-11-04","lastUpdatePostDateStruct":{"date":"2016-11-06","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merz Pharmaceuticals GmbH","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the leg are effective in treating patients with increased muscle tension/uncontrollable muscle stiffness (spasticity) after a stroke."},"conditionsModule":{"conditions":["Post-stroke Spasticity of the Lower Limb"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":290,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"IncobotulinumtoxinA (Xeomin) 400 Units","type":"EXPERIMENTAL","description":"IncobotulinumtoxinA (Xeomin, also known as \"NT 201\" or \"Botulinum toxin type A (150 kiloDalton), free from complexing proteins\") (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.","interventionNames":["Drug: IncobotulinumtoxinA (400 Units)"]},{"label":"Placebo Comparator Arm","type":"PLACEBO_COMPARATOR","description":"Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.","interventionNames":["Drug: Placebo Comparator"]}],"interventions":[{"type":"DRUG","name":"IncobotulinumtoxinA (400 Units)","description":"Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.","armGroupLabels":["IncobotulinumtoxinA (Xeomin) 400 Units"]},{"type":"DRUG","name":"Placebo Comparator","description":"Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection","armGroupLabels":["Placebo Comparator Arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Ashworth Scale (AS) for Plantar Flexors at Week 4","description":"The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Baseline and Week 4"},{"measure":"Co-primary Variable: Investigator's Global Assessment of Efficacy at Week 12","description":"A 4-point Likert scale will be used with the ratings 1 = very good, 2 = good, 3 = moderate, and 4 = poor. Investigator's Global Assessment of Efficacy at Week 12 will be a co-primary outcome measure to fulfill post marketing commitments for U.S. regulatory authorities only. Elsewhere, it will be a secondary outcome measure.","timeFrame":"Baseline to Week 12"}],"secondaryOutcomes":[{"measure":"Response Rate for Plantar Flexors at All Post-Baseline Visits for Subjects With an Improvement (Reduction) of at Least 1 Point From Baseline in the Ashworth Scale (AS)","description":"Response is defined as an improvement (reduction) of the plantar flexor Ashworth Score by at least one score point. The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","timeFrame":"Week 4, 8, and 12"},{"measure":"Ashworth Scale (AS) for Plantar Flexors at All Post-Baseline Visits","description":"The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Here, 'n' specifies those subjects who were evaluated for this outcome measure at given time point.","timeFrame":"Baseline, Week 4, 8, and 12"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age from 18-80 yrs\n* Lower limb spasticity\n* Time since stroke greater than 3 months\n* Need for 400 U Botulinum toxin type A\n\nExclusion Criteria:\n\n* Body weight below 50kg\n* Fixed contractures of the lower limb\n* Generalized disorders of muscle activity like Myasthenia gravis that preclude use of Botulinum toxin type A\n* Infection at the injection site","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Expert","affiliation":"Merz Pharmaceuticals GmbH","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Merz Investigational Site #001184","city":"Downey","state":"California","zip":"90242","country":"United States","geoPoint":{"lat":33.94001,"lon":-118.13257}},{"facility":"Merz Investigational Site #001208","city":"Long Beach","state":"California","zip":"90806","country":"United States","geoPoint":{"lat":33.76696,"lon":-118.18923}},{"facility":"Merz Investigational Site #001244","city":"Fairfield","state":"Connecticut","zip":"06824","country":"United States","geoPoint":{"lat":41.14121,"lon":-73.26373}},{"facility":"Investigational site #001188","city":"Doral","state":"Florida","zip":"33172","country":"United States","geoPoint":{"lat":25.81954,"lon":-80.35533}},{"facility":"Merz Investigational Site # 001110","city":"Overland Park","state":"Kansas","zip":"66211","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"facility":"Merz Investigational Site #001209","city":"Columbia","state":"Missouri","zip":"65212","country":"United States","geoPoint":{"lat":38.95171,"lon":-92.33407}},{"facility":"Merz Investigational Site #001210","city":"St. Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Merz Investigational Site #001198","city":"Stratford","state":"New Jersey","zip":"08084","country":"United States","geoPoint":{"lat":39.82678,"lon":-75.01545}},{"facility":"Merz Investigational Site #001207","city":"Plainview","state":"New York","zip":"11803","country":"United States","geoPoint":{"lat":40.77649,"lon":-73.46735}},{"facility":"Merz Investigational Site #001009","city":"Winston-Salem","state":"North Carolina","zip":"27157","country":"United States","geoPoint":{"lat":36.09986,"lon":-80.24422}},{"facility":"Merz Investigational Site #001206","city":"Nashville","state":"Tennessee","zip":"37232","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Merz Investigational Site #001183","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Merz Investigational Site #001204","city":"Halifax","state":"Nova Scotia","zip":"B3H 4K4","country":"Canada","geoPoint":{"lat":44.64533,"lon":-63.57239}},{"facility":"Merz Investigational Site #001202","city":"Winnipeg","zip":"MB R3A 1M4","country":"Canada","geoPoint":{"lat":49.8844,"lon":-97.14704}},{"facility":"Merz Investigational Site #420024","city":"Ostrava-Poruba","zip":"70852","country":"Czech Republic","geoPoint":{"lat":49.83465,"lon":18.28204}},{"facility":"Merz Investigational Site #420031","city":"Ostrava-Vitkovice","zip":"70384","country":"Czech Republic","geoPoint":{"lat":49.83465,"lon":18.28204}},{"facility":"Merz Investigational Site #420030","city":"Praha","zip":"12000","country":"Czech Republic","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Merz Investigational Site #420047","city":"Rychnov nad Kneznou","zip":"51601","country":"Czech Republic","geoPoint":{"lat":50.16284,"lon":16.27488}},{"facility":"Merz Investigational Site #033018","city":"Garches","zip":"92380","country":"France","geoPoint":{"lat":48.84226,"lon":2.18232}},{"facility":"Merz Investigational Site #033024","city":"Rennes","zip":"35043","country":"France","geoPoint":{"lat":48.11198,"lon":-1.67429}},{"facility":"Merz Investigational Site #049022","city":"Beelitz-Heilstätten","zip":"14547","country":"Germany","geoPoint":{"lat":52.25965,"lon":12.92662}},{"facility":"Merz Investigational Site #049071","city":"Düsseldorf","zip":"40225","country":"Germany","geoPoint":{"lat":51.22172,"lon":6.77616}},{"facility":"Merz Investigational Site #049079","city":"Hamburg","zip":"20246","country":"Germany","geoPoint":{"lat":53.57532,"lon":10.01534}},{"facility":"Merz Investigational Site #049304","city":"Kiel","zip":"24105","country":"Germany","geoPoint":{"lat":54.32133,"lon":10.13489}},{"facility":"Merz Investigational Site #049072","city":"München","zip":"80804","country":"Germany","geoPoint":{"lat":48.13743,"lon":11.57549}},{"facility":"Merz Investigational Site #049148","city":"München","zip":"81675","country":"Germany","geoPoint":{"lat":48.13743,"lon":11.57549}},{"facility":"Merz Investigational Site #049303","city":"Regensburg","zip":"93053","country":"Germany","geoPoint":{"lat":49.01513,"lon":12.10161}},{"facility":"Merz Investigational Site #049302","city":"Würzburg","zip":"97080","country":"Germany","geoPoint":{"lat":49.79391,"lon":9.95121}},{"facility":"Merz Investigational Site #039006","city":"Messina","zip":"98125","country":"Italy","geoPoint":{"lat":38.19394,"lon":15.55256}},{"facility":"Merz Investigational Site #039011","city":"Roma","zip":"00168","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Merz Investigational Site #039012","city":"Roma","zip":"00189","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Merz Investigational Site #048057","city":"Gdansk","zip":"80-462","country":"Poland","geoPoint":{"lat":54.35205,"lon":18.64637}},{"facility":"Merz Investigational Site #048044","city":"Kielce","zip":"25-103","country":"Poland","geoPoint":{"lat":50.87033,"lon":20.62752}},{"facility":"Merz Investigational Site #048080","city":"Krakow","zip":"30-349","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Merz Investigational Site #048054","city":"Krakow","zip":"30-510","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Merz Investigational Site #048031","city":"Krakow","zip":"31-505","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"Merz Investigational Site #048022","city":"Lodz","zip":"90-130","country":"Poland","geoPoint":{"lat":51.75,"lon":19.46667}},{"facility":"Merz Investigational Site #048051","city":"Lublin","zip":"20-022","country":"Poland","geoPoint":{"lat":51.25,"lon":22.56667}},{"facility":"Merz Investigational Site #048053","city":"Poznan","zip":"61-485","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Merz Investigational Site #048081","city":"Poznan","zip":"61-853","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"Merz Investigational Site #048055","city":"Warszawa","zip":"01-697","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Merz Investigational Site #048023","city":"Warszawa","zip":"02-957","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Merz Investigational Site #048056","city":"Warszawa","zip":"02097","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Merz Investigational Site #048033","city":"Warszawa","zip":"04-749","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Merz Investigational Site #007010","city":"Krasnoyarsk","zip":"660037","country":"Russian Federation","geoPoint":{"lat":56.01839,"lon":92.86717}},{"facility":"Merz Investigational Site #007011","city":"Moscow","zip":"105005","country":"Russian Federation","geoPoint":{"lat":55.75222,"lon":37.61556}},{"facility":"Merz Investigational Site #007009","city":"St. Petersburg","zip":"129019","country":"Russian Federation","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Merz Investigational Site #007012","city":"Stavropol","zip":"355000","country":"Russian Federation","geoPoint":{"lat":45.0428,"lon":41.9734}},{"facility":"Merz Investigational Site #034027","city":"Madrid","zip":"28040","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Merz Investigational Site #034028","city":"Majadahonda","zip":"28222","country":"Spain","geoPoint":{"lat":40.47353,"lon":-3.87182}},{"facility":"Merz Investigational Site #034026","city":"Sevilla","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Merz Investigational Site #034030","city":"Sevilla","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Merz Investigational Site #034029","city":"Terrassa","zip":"08221","country":"Spain","geoPoint":{"lat":41.56667,"lon":2.01667}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 290 subjects were enrolled in study. One ineligible subject was randomized to placebo but withdrawn from study prior to first treatment with study medication. A total of 289 subjects were enrolled in main period. All of the 269 subjects who completed the main period of the study entered the open-label extension period.","recruitmentDetails":"A total of 331 individuals suffering from post-stroke lower-limb spasticity were screened and 290 were included in study at 51 sites. One ineligible subject was randomized to placebo but withdrawn from study prior to first treatment with study medication. For purpose of study analysis overall number of subjects enrolled is therefore considered 289.","groups":[{"id":"FG000","title":"IncobotulinumtoxinA (Xeomin) 400 Units","description":"IncobotulinumtoxinA (Xeomin, also known as \"NT 201\" or \"Botulinum toxin type A (150 kiloDalton), free from complexing proteins\") (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.\n\nIncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9 percent (%) Sodium Chloride (NaCl), 400 units, total volume 8.0 milliliter (mL); Mode of administration: intramuscular injection.\n\nIncobotulinumtoxinA (400 Units): Open-Label Extension Period: All subjects receive three injection sessions of solution, prepared by reconstitution of powder with 0.9% NaCl, 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection."},{"id":"FG001","title":"Placebo","description":"Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.\n\nPlacebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection"}],"periods":[{"title":"Main Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"144"},{"groupId":"FG001","numSubjects":"145"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"144"},{"groupId":"FG001","numSubjects":"145"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"129"},{"groupId":"FG001","numSubjects":"140"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"5"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Predefined discontinuation criteria","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]}]},{"title":"Open-Label Extension Period","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"269"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"269"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"218"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"51"},{"groupId":"FG001","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Non-compliance","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Predefined discontinuation criteria","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The Safety Evaluation Set (SES) is the subset of all subjects who were exposed to Investigational product (IP) in the main period at least once.","groups":[{"id":"BG000","title":"Main Period: IncobotulinumtoxinA (Xeomin) 400 Units","description":"IncobotulinumtoxinA (Xeomin, also known as \"NT 201\" or \"Botulinum toxin type A (150 kiloDalton), free from complexing proteins\") (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.\n\nIncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection."},{"id":"BG001","title":"Main Period: Placebo","description":"Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.\n\nPlacebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"144"},{"groupId":"BG001","value":"145"},{"groupId":"BG002","value":"289"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"57.3","spread":"11.2"},{"groupId":"BG001","value":"57.0","spread":"13.0"},{"groupId":"BG002","value":"57.2","spread":"12.1"}]}]}]},{"title":"Gender","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"95"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"194"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Ashworth Scale (AS) for Plantar Flexors at Week 4","description":"The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"The Full Analysis Set (FAS) included subjects in the Safety Evaluation Set (SES) of the main period for whom the primary efficacy variable was available, whereby SES is the subset of all subjects who were exposed to IP in the main period at least once.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on a scale","timeFrame":"Baseline and Week 4","groups":[{"id":"OG000","title":"IncobotulinumtoxinA (Xeomin) 400 Units","description":"IncobotulinumtoxinA (Xeomin, also known as \"NT 201\" or \"Botulinum toxin type A (150 kiloDalton), free from complexing proteins\") (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.\n\nIncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection."},{"id":"OG001","title":"Placebo","description":"Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.\n\nPlacebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"145"}]}],"classes":[{"title":"Baseline","categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"0.7"},{"groupId":"OG001","value":"2.8","spread":"0.7"}]}]},{"title":"Change at Week 4","categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.7"},{"groupId":"OG001","value":"-0.4","spread":"0.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The number of subjects included in the MMRM analysis was only 286 because a covariate was missing for 3 subjects.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.777","statisticalMethod":"Mixed-Model Repeated Measures","paramType":"Least Square Mean Difference","paramValue":"0.0","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.1","ciUpperLimit":"0.2"}]},{"type":"PRIMARY","title":"Co-primary Variable: Investigator's Global Assessment of Efficacy at Week 12","description":"A 4-point Likert scale will be used with the ratings 1 = very good, 2 = good, 3 = moderate, and 4 = poor. Investigator's Global Assessment of Efficacy at Week 12 will be a co-primary outcome measure to fulfill post marketing commitments for U.S. regulatory authorities only. Elsewhere, it will be a secondary outcome measure.","populationDescription":"The Full Analysis Set (FAS) included subjects in the Safety Evaluation Set (SES) of the main period for whom the primary efficacy variable was available, whereby SES is the subset of all subjects who were exposed to IP in the main period at least once.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline to Week 12","groups":[{"id":"OG000","title":"IncobotulinumtoxinA (Xeomin) 400 Units","description":"IncobotulinumtoxinA (Xeomin, also known as \"NT 201\" or \"Botulinum toxin type A (150 kiloDalton), free from complexing proteins\") (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.\n\nIncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection."},{"id":"OG001","title":"Placebo","description":"Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.\n\nPlacebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"145"}]}],"classes":[{"title":"Very good","categories":[{"measurements":[{"groupId":"OG000","value":"3.5"},{"groupId":"OG001","value":"4.8"}]}]},{"title":"Good","categories":[{"measurements":[{"groupId":"OG000","value":"28.5"},{"groupId":"OG001","value":"22.8"}]}]},{"title":"Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"26.9"}]}]},{"title":"Poor","categories":[{"measurements":[{"groupId":"OG000","value":"45.8"},{"groupId":"OG001","value":"45.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"The statistical analysis provided was for all categories of this outcome measure.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.804","pValueComment":"worst-case analysis.","statisticalMethod":"Wilcoxon's Rank-Sum Test"}]},{"type":"SECONDARY","title":"Response Rate for Plantar Flexors at All Post-Baseline Visits for Subjects With an Improvement (Reduction) of at Least 1 Point From Baseline in the Ashworth Scale (AS)","description":"Response is defined as an improvement (reduction) of the plantar flexor Ashworth Score by at least one score point. The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).","populationDescription":"The FAS included subjects in SES of main period for whom primary efficacy variable was available, whereby SES is subset of all subjects who were exposed to IP in main period at least once. Here, \"N\"(Number of Participants Analyzed) and \"n\" signifies those participants who were evaluable for this outcome measure and at given time point respectively.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Week 4, 8, and 12","groups":[{"id":"OG000","title":"IncobotulinumtoxinA (Xeomin) 400 Units","description":"IncobotulinumtoxinA (Xeomin, also known as \"NT 201\" or \"Botulinum toxin type A (150 kiloDalton), free from complexing proteins\") (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.\n\nIncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection."},{"id":"OG001","title":"Placebo","description":"Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.\n\nPlacebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"144"}]}],"classes":[{"title":"Week 4 (n=142, 144)","categories":[{"measurements":[{"groupId":"OG000","value":"37.3"},{"groupId":"OG001","value":"35.4"}]}]},{"title":"Week 8 (n=140, 142)","categories":[{"measurements":[{"groupId":"OG000","value":"39.3"},{"groupId":"OG001","value":"33.8"}]}]},{"title":"Week 12 (n=135, 141)","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"17"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Week 4. Number of subjects included in analysis was three less than the observed cases because of a missing covariate for the logistic regression analysis, that is, n=283 for week 4.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.845","pValueComment":"observed cases analysis.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.05","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"1.74"},{"groupIds":["OG000","OG001"],"groupDescription":"Week 8. Number of subjects included in analysis was three less than the observed cases because of a missing covariate for the logistic regression analysis, that is, n=279 for week 8.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.437","pValueComment":"observed cases analysis.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.23","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.73","ciUpperLimit":"2.04"},{"groupIds":["OG000","OG001"],"groupDescription":"Week 12. Number of subjects included in analysis was three less than the observed cases because of a missing covariate for the logistic regression analysis, that is, n=273 for week 12.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.698","pValueComment":"observed cases analysis.","statisticalMethod":"Regression, Logistic","paramType":"Odds Ratio (OR)","paramValue":"1.14","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.59","ciUpperLimit":"2.21"}]},{"type":"SECONDARY","title":"Ashworth Scale (AS) for Plantar Flexors at All Post-Baseline Visits","description":"The AS is a well known and commonly used scale in clinical trials with spasticity. It was considered to be the best clinical tool for measuring resistance to movement. It was used to categorize the severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension). Here, 'n' specifies those subjects who were evaluated for this outcome measure at given time point.","populationDescription":"The Full Analysis Set (FAS) included subjects in the Safety Evaluation Set (SES) of the main period for whom the primary efficacy variable was available, whereby SES is the subset of all subjects who were exposed to IP in the main period at least once.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on a scale","timeFrame":"Baseline, Week 4, 8, and 12","groups":[{"id":"OG000","title":"IncobotulinumtoxinA (Xeomin) 400 Units","description":"IncobotulinumtoxinA (Xeomin, also known as \"NT 201\" or \"Botulinum toxin type A (150 kiloDalton), free from complexing proteins\") (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.\n\nIncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection."},{"id":"OG001","title":"Placebo","description":"Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.\n\nPlacebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"145"}]}],"classes":[{"title":"Baseline (n=144, 145)","categories":[{"measurements":[{"groupId":"OG000","value":"2.8","spread":"0.7"},{"groupId":"OG001","value":"2.8","spread":"0.7"}]}]},{"title":"Week 4 (n= 142, 144)","categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"0.9"},{"groupId":"OG001","value":"2.4","spread":"0.8"}]}]},{"title":"Week 8 (n=140, 142)","categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":"0.9"},{"groupId":"OG001","value":"2.5","spread":"0.7"}]}]},{"title":"Week 12 (n= 135, 141)","categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"0.8"},{"groupId":"OG001","value":"2.7","spread":"0.7"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"2","timeFrame":"From time point of first injection until 120 +/- 7 days after last administration of injection","description":"The investigator asked the subject for adverse events systematically at each visit.","eventGroups":[{"id":"EG000","title":"Main Period: IncobotulinumtoxinA (Xeomin) 400 Units","description":"IncobotulinumtoxinA (Xeomin, also known as \"NT 201\" or \"Botulinum toxin type A (150 kiloDalton), free from complexing proteins\") (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.\n\nIncobotulinumtoxinA (400 Units): Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.","seriousNumAffected":6,"seriousNumAtRisk":144,"otherNumAffected":13,"otherNumAtRisk":144},{"id":"EG001","title":"Main Period: Placebo","description":"Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection.\n\nPlacebo Comparator: Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection","seriousNumAffected":5,"seriousNumAtRisk":145,"otherNumAffected":13,"otherNumAtRisk":145},{"id":"EG002","title":"Open-Label Extension: IncobotulinumtoxinA (Xeomin) 400 Units","description":"IncobotulinumtoxinA (Xeomin, also known as \"NT 201\" or \"Botulinum toxin type A (150 kiloDalton), free from complexing proteins\") (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.\n\nIncobotulinumtoxinA (400 Units): Open-Label Extension Period: All subjects receive three injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.","seriousNumAffected":22,"seriousNumAtRisk":269,"otherNumAffected":31,"otherNumAtRisk":269}],"seriousEvents":[{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":2,"numAtRisk":269}]},{"term":"Intracranial haematoma","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":1,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Jaundice cholestatic","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Fractured sacrum","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Spinal fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Malnutrition","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Mobility decreased","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":1,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Pancreatic neoplasm","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Cranioplasty","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":1,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":1,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":1,"numAtRisk":145},{"groupId":"EG002","numAffected":0,"numAtRisk":269}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":1,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Adenocarcinoma of colon","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Uterine leiomyoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Desmoid tumour","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Medical induction of coma","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Skin lesion excision","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Tracheostomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Limb operation","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Rehabilitation therapy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Staphylococcal bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Patella fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Face injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Upper-limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Personality disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Uterine polyp","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Immobile","organSystem":"Social circumstances","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Haemolytic anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Foot deformity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":144},{"groupId":"EG001","numAffected":0,"numAtRisk":145},{"groupId":"EG002","numAffected":1,"numAtRisk":269}]}],"otherEvents":[{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":144},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":145},{"groupId":"EG002","numEvents":10,"numAffected":10,"numAtRisk":269}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":144},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":145},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":269}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":144},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":145},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":269}]},{"term":"Vision blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":145},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":269}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":144},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":145},{"groupId":"EG002","numEvents":12,"numAffected":11,"numAtRisk":269}]},{"term":"γ-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":145},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":269}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":144},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":145},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":269}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":144},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":145},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":269}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Publication of study information usually requires agreement with the sponsor. In case of justified doubts by the sponsor, the Investigator will consider these doubts in the publication as long as the scientific neutrality is not affected."},"pointOfContact":{"title":"Public Disclosure Manager","organization":"Merz Pharmaceuticals GmbH","email":"clinicaltrials@merz.de","phone":"+49 69 1503 1"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Austria"]},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"C000545476","term":"incobotulinumtoxinA"}],"ancestors":[{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","relevance":"LOW"},{"id":"M250157","name":"abobotulinumtoxinA","relevance":"LOW"},{"id":"M20947","name":"Botulinum Toxins, Type A","relevance":"LOW"},{"id":"M250251","name":"incobotulinumtoxinA","asFound":"Afatinib","relevance":"HIGH"},{"id":"M21550","name":"Pharmaceutical Solutions","relevance":"LOW"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"PhSol","name":"Pharmaceutical Solutions"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":true}